Association of heme-oxygenase 1, hemopexin, and heme levels with markers of disease severity in COVID-19
Heme-oxygenase 1 (HO-1) is an enzyme with well-known anti-inflammatory and antioxidant properties, whose levels have been previously associated with disease severity in the context of sterile and infectious diseases. Moreover, the heme/HO-1 pathway has been associated with prothrombotic changes in o...
Gespeichert in:
| Veröffentlicht in: | Experimental biology and medicine (Maywood, N.J.) N.J.), 2023-02, Vol.248 (4), p.309-316 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 316 |
|---|---|
| container_issue | 4 |
| container_start_page | 309 |
| container_title | Experimental biology and medicine (Maywood, N.J.) |
| container_volume | 248 |
| creator | de Lima, Franciele Moraes, Carla Roberta Peachazepi Barbosa, Mayck Silva Bombassaro, Bruna Palma, André C Dertkigil, Sergio San Juan Moretti, Maria Luiza Orsi, Fernanda Andrade Annichino-Bizzacchi, Joyce M Mansour, Eli Velloso, Licio A De Paula, Erich Vinicius |
| description | Heme-oxygenase 1 (HO-1) is an enzyme with well-known anti-inflammatory and antioxidant properties, whose levels have been previously associated with disease severity in the context of sterile and infectious diseases. Moreover, the heme/HO-1 pathway has been associated with prothrombotic changes in other diseases. Accordingly, the potential of modulating HO-1 levels for the treatment of COVID-19 was extensively speculated during the COVID-19 pandemic, but very few actual data were generated. The aim of our study was to explore the association of HO-1, heme, and hemopexin (HPX) levels with COVID-19 severity and with markers of inflammation and coagulation activation. The study was conducted in 30 consecutive patients with COVID-19 admitted due to hypoxemia, and 30 healthy volunteers matched by sex, age, and geographic region. HO-1 and HPX levels were measured by enzyme immunoassay (ELISA) and heme levels were measured by a colorimetric method. A comprehensive panel of coagulation and fibrinolysis activation was also used. Patients with COVID-19 presented increased levels of HO-1 when compared to controls (5741 ± 2696 vs 1953 ± 612 pg/mL, respectively, P |
| doi_str_mv | 10.1177/15353702221139185 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9902789</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.1177_15353702221139185</sage_id><sourcerecordid>2773719462</sourcerecordid><originalsourceid>FETCH-LOGICAL-c438t-226083150fac4f9d66f2c45ea16364b646693a45eadb3436ce150e15abb7008c3</originalsourceid><addsrcrecordid>eNp9kUtrGzEUhUVJqZ3HD-imaJlFJtFjRhptCsFtHmDIpu1WaDR3bLljyZXGSfzvo6mTkFDoQkic-51zL7oIfabknFIpL2jFKy4JY4xSrmhdfUDTUSu4UOrg5Z2BCTpMaUUIrSQTn9CEC1kSWYkpWl6mFKwzgwsehw4vYQ1FeNwtwJsEmJ6NStjAo_Nn2Pj2L4B7uIc-4Qc3LPHaxN8Q02huXYLRlXI5umGHncezu1-33wqqjtHHzvQJTp7vI_Tz6vuP2U0xv7u-nV3OC1vyeigYE6TmtCKdsWWnWiE6ZssKDBVclI0ohVDcjELb8JILC5nNxzSNJKS2_Ah93eduts0aWgt-iKbXm-jyoDsdjNPvK94t9SLca6UIk7XKAafPATH82UIa9NolC31vPIRt0kxKLqkqBcso3aM2hpQidK9tKNHjhvQ_G8qeL2_ne3W8rCQD53sgmQXoVdhGn__rP4lPKrKYvw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2773719462</pqid></control><display><type>article</type><title>Association of heme-oxygenase 1, hemopexin, and heme levels with markers of disease severity in COVID-19</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><creator>de Lima, Franciele ; Moraes, Carla Roberta Peachazepi ; Barbosa, Mayck Silva ; Bombassaro, Bruna ; Palma, André C ; Dertkigil, Sergio San Juan ; Moretti, Maria Luiza ; Orsi, Fernanda Andrade ; Annichino-Bizzacchi, Joyce M ; Mansour, Eli ; Velloso, Licio A ; De Paula, Erich Vinicius</creator><creatorcontrib>de Lima, Franciele ; Moraes, Carla Roberta Peachazepi ; Barbosa, Mayck Silva ; Bombassaro, Bruna ; Palma, André C ; Dertkigil, Sergio San Juan ; Moretti, Maria Luiza ; Orsi, Fernanda Andrade ; Annichino-Bizzacchi, Joyce M ; Mansour, Eli ; Velloso, Licio A ; De Paula, Erich Vinicius</creatorcontrib><description>Heme-oxygenase 1 (HO-1) is an enzyme with well-known anti-inflammatory and antioxidant properties, whose levels have been previously associated with disease severity in the context of sterile and infectious diseases. Moreover, the heme/HO-1 pathway has been associated with prothrombotic changes in other diseases. Accordingly, the potential of modulating HO-1 levels for the treatment of COVID-19 was extensively speculated during the COVID-19 pandemic, but very few actual data were generated. The aim of our study was to explore the association of HO-1, heme, and hemopexin (HPX) levels with COVID-19 severity and with markers of inflammation and coagulation activation. The study was conducted in 30 consecutive patients with COVID-19 admitted due to hypoxemia, and 30 healthy volunteers matched by sex, age, and geographic region. HO-1 and HPX levels were measured by enzyme immunoassay (ELISA) and heme levels were measured by a colorimetric method. A comprehensive panel of coagulation and fibrinolysis activation was also used. Patients with COVID-19 presented increased levels of HO-1 when compared to controls (5741 ± 2696 vs 1953 ± 612 pg/mL, respectively, P < 0.0001), as well as a trend toward increased levels of HPX (3.724 ± 0.880 vs 3.254 ± 1.022 mg/mL, respectively; P = 0.06). In addition, HO-1 and HPX levels reduced from admission to day + 4. HO-1 levels were associated with duration of intensive care unit stay and with several markers of coagulation activation. In conclusion, modulation of HO-1 could be associated with the prothrombotic state observed in COVID-19, and HO-1 could also represent a relevant biomarker for COVID-19. New independent studies are warranted to explore and expand these findings.</description><identifier>ISSN: 1535-3702</identifier><identifier>EISSN: 1535-3699</identifier><identifier>DOI: 10.1177/15353702221139185</identifier><identifier>PMID: 36740756</identifier><language>eng</language><publisher>London, England: SAGE Publications</publisher><subject>Biomarkers ; Brief Communication ; COVID-19 ; Heme ; Heme Oxygenase-1 - metabolism ; Hemopexin - metabolism ; Humans ; Pandemics ; Patient Acuity</subject><ispartof>Experimental biology and medicine (Maywood, N.J.), 2023-02, Vol.248 (4), p.309-316</ispartof><rights>2023 by the Society for Experimental Biology and Medicine</rights><rights>2023 by the Society for Experimental Biology and Medicine 2023 The Society for Experimental Biology and Medicine</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c438t-226083150fac4f9d66f2c45ea16364b646693a45eadb3436ce150e15abb7008c3</citedby><cites>FETCH-LOGICAL-c438t-226083150fac4f9d66f2c45ea16364b646693a45eadb3436ce150e15abb7008c3</cites><orcidid>0000-0002-8698-2388 ; 0000-0002-2280-5649 ; 0000-0003-1539-7912 ; 0000-0001-6450-6930</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9902789/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9902789/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36740756$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>de Lima, Franciele</creatorcontrib><creatorcontrib>Moraes, Carla Roberta Peachazepi</creatorcontrib><creatorcontrib>Barbosa, Mayck Silva</creatorcontrib><creatorcontrib>Bombassaro, Bruna</creatorcontrib><creatorcontrib>Palma, André C</creatorcontrib><creatorcontrib>Dertkigil, Sergio San Juan</creatorcontrib><creatorcontrib>Moretti, Maria Luiza</creatorcontrib><creatorcontrib>Orsi, Fernanda Andrade</creatorcontrib><creatorcontrib>Annichino-Bizzacchi, Joyce M</creatorcontrib><creatorcontrib>Mansour, Eli</creatorcontrib><creatorcontrib>Velloso, Licio A</creatorcontrib><creatorcontrib>De Paula, Erich Vinicius</creatorcontrib><title>Association of heme-oxygenase 1, hemopexin, and heme levels with markers of disease severity in COVID-19</title><title>Experimental biology and medicine (Maywood, N.J.)</title><addtitle>Exp Biol Med (Maywood)</addtitle><description>Heme-oxygenase 1 (HO-1) is an enzyme with well-known anti-inflammatory and antioxidant properties, whose levels have been previously associated with disease severity in the context of sterile and infectious diseases. Moreover, the heme/HO-1 pathway has been associated with prothrombotic changes in other diseases. Accordingly, the potential of modulating HO-1 levels for the treatment of COVID-19 was extensively speculated during the COVID-19 pandemic, but very few actual data were generated. The aim of our study was to explore the association of HO-1, heme, and hemopexin (HPX) levels with COVID-19 severity and with markers of inflammation and coagulation activation. The study was conducted in 30 consecutive patients with COVID-19 admitted due to hypoxemia, and 30 healthy volunteers matched by sex, age, and geographic region. HO-1 and HPX levels were measured by enzyme immunoassay (ELISA) and heme levels were measured by a colorimetric method. A comprehensive panel of coagulation and fibrinolysis activation was also used. Patients with COVID-19 presented increased levels of HO-1 when compared to controls (5741 ± 2696 vs 1953 ± 612 pg/mL, respectively, P < 0.0001), as well as a trend toward increased levels of HPX (3.724 ± 0.880 vs 3.254 ± 1.022 mg/mL, respectively; P = 0.06). In addition, HO-1 and HPX levels reduced from admission to day + 4. HO-1 levels were associated with duration of intensive care unit stay and with several markers of coagulation activation. In conclusion, modulation of HO-1 could be associated with the prothrombotic state observed in COVID-19, and HO-1 could also represent a relevant biomarker for COVID-19. New independent studies are warranted to explore and expand these findings.</description><subject>Biomarkers</subject><subject>Brief Communication</subject><subject>COVID-19</subject><subject>Heme</subject><subject>Heme Oxygenase-1 - metabolism</subject><subject>Hemopexin - metabolism</subject><subject>Humans</subject><subject>Pandemics</subject><subject>Patient Acuity</subject><issn>1535-3702</issn><issn>1535-3699</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kUtrGzEUhUVJqZ3HD-imaJlFJtFjRhptCsFtHmDIpu1WaDR3bLljyZXGSfzvo6mTkFDoQkic-51zL7oIfabknFIpL2jFKy4JY4xSrmhdfUDTUSu4UOrg5Z2BCTpMaUUIrSQTn9CEC1kSWYkpWl6mFKwzgwsehw4vYQ1FeNwtwJsEmJ6NStjAo_Nn2Pj2L4B7uIc-4Qc3LPHaxN8Q02huXYLRlXI5umGHncezu1-33wqqjtHHzvQJTp7vI_Tz6vuP2U0xv7u-nV3OC1vyeigYE6TmtCKdsWWnWiE6ZssKDBVclI0ohVDcjELb8JILC5nNxzSNJKS2_Ah93eduts0aWgt-iKbXm-jyoDsdjNPvK94t9SLca6UIk7XKAafPATH82UIa9NolC31vPIRt0kxKLqkqBcso3aM2hpQidK9tKNHjhvQ_G8qeL2_ne3W8rCQD53sgmQXoVdhGn__rP4lPKrKYvw</recordid><startdate>20230201</startdate><enddate>20230201</enddate><creator>de Lima, Franciele</creator><creator>Moraes, Carla Roberta Peachazepi</creator><creator>Barbosa, Mayck Silva</creator><creator>Bombassaro, Bruna</creator><creator>Palma, André C</creator><creator>Dertkigil, Sergio San Juan</creator><creator>Moretti, Maria Luiza</creator><creator>Orsi, Fernanda Andrade</creator><creator>Annichino-Bizzacchi, Joyce M</creator><creator>Mansour, Eli</creator><creator>Velloso, Licio A</creator><creator>De Paula, Erich Vinicius</creator><general>SAGE Publications</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-8698-2388</orcidid><orcidid>https://orcid.org/0000-0002-2280-5649</orcidid><orcidid>https://orcid.org/0000-0003-1539-7912</orcidid><orcidid>https://orcid.org/0000-0001-6450-6930</orcidid></search><sort><creationdate>20230201</creationdate><title>Association of heme-oxygenase 1, hemopexin, and heme levels with markers of disease severity in COVID-19</title><author>de Lima, Franciele ; Moraes, Carla Roberta Peachazepi ; Barbosa, Mayck Silva ; Bombassaro, Bruna ; Palma, André C ; Dertkigil, Sergio San Juan ; Moretti, Maria Luiza ; Orsi, Fernanda Andrade ; Annichino-Bizzacchi, Joyce M ; Mansour, Eli ; Velloso, Licio A ; De Paula, Erich Vinicius</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c438t-226083150fac4f9d66f2c45ea16364b646693a45eadb3436ce150e15abb7008c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Biomarkers</topic><topic>Brief Communication</topic><topic>COVID-19</topic><topic>Heme</topic><topic>Heme Oxygenase-1 - metabolism</topic><topic>Hemopexin - metabolism</topic><topic>Humans</topic><topic>Pandemics</topic><topic>Patient Acuity</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>de Lima, Franciele</creatorcontrib><creatorcontrib>Moraes, Carla Roberta Peachazepi</creatorcontrib><creatorcontrib>Barbosa, Mayck Silva</creatorcontrib><creatorcontrib>Bombassaro, Bruna</creatorcontrib><creatorcontrib>Palma, André C</creatorcontrib><creatorcontrib>Dertkigil, Sergio San Juan</creatorcontrib><creatorcontrib>Moretti, Maria Luiza</creatorcontrib><creatorcontrib>Orsi, Fernanda Andrade</creatorcontrib><creatorcontrib>Annichino-Bizzacchi, Joyce M</creatorcontrib><creatorcontrib>Mansour, Eli</creatorcontrib><creatorcontrib>Velloso, Licio A</creatorcontrib><creatorcontrib>De Paula, Erich Vinicius</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Experimental biology and medicine (Maywood, N.J.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>de Lima, Franciele</au><au>Moraes, Carla Roberta Peachazepi</au><au>Barbosa, Mayck Silva</au><au>Bombassaro, Bruna</au><au>Palma, André C</au><au>Dertkigil, Sergio San Juan</au><au>Moretti, Maria Luiza</au><au>Orsi, Fernanda Andrade</au><au>Annichino-Bizzacchi, Joyce M</au><au>Mansour, Eli</au><au>Velloso, Licio A</au><au>De Paula, Erich Vinicius</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Association of heme-oxygenase 1, hemopexin, and heme levels with markers of disease severity in COVID-19</atitle><jtitle>Experimental biology and medicine (Maywood, N.J.)</jtitle><addtitle>Exp Biol Med (Maywood)</addtitle><date>2023-02-01</date><risdate>2023</risdate><volume>248</volume><issue>4</issue><spage>309</spage><epage>316</epage><pages>309-316</pages><issn>1535-3702</issn><eissn>1535-3699</eissn><abstract>Heme-oxygenase 1 (HO-1) is an enzyme with well-known anti-inflammatory and antioxidant properties, whose levels have been previously associated with disease severity in the context of sterile and infectious diseases. Moreover, the heme/HO-1 pathway has been associated with prothrombotic changes in other diseases. Accordingly, the potential of modulating HO-1 levels for the treatment of COVID-19 was extensively speculated during the COVID-19 pandemic, but very few actual data were generated. The aim of our study was to explore the association of HO-1, heme, and hemopexin (HPX) levels with COVID-19 severity and with markers of inflammation and coagulation activation. The study was conducted in 30 consecutive patients with COVID-19 admitted due to hypoxemia, and 30 healthy volunteers matched by sex, age, and geographic region. HO-1 and HPX levels were measured by enzyme immunoassay (ELISA) and heme levels were measured by a colorimetric method. A comprehensive panel of coagulation and fibrinolysis activation was also used. Patients with COVID-19 presented increased levels of HO-1 when compared to controls (5741 ± 2696 vs 1953 ± 612 pg/mL, respectively, P < 0.0001), as well as a trend toward increased levels of HPX (3.724 ± 0.880 vs 3.254 ± 1.022 mg/mL, respectively; P = 0.06). In addition, HO-1 and HPX levels reduced from admission to day + 4. HO-1 levels were associated with duration of intensive care unit stay and with several markers of coagulation activation. In conclusion, modulation of HO-1 could be associated with the prothrombotic state observed in COVID-19, and HO-1 could also represent a relevant biomarker for COVID-19. New independent studies are warranted to explore and expand these findings.</abstract><cop>London, England</cop><pub>SAGE Publications</pub><pmid>36740756</pmid><doi>10.1177/15353702221139185</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0002-8698-2388</orcidid><orcidid>https://orcid.org/0000-0002-2280-5649</orcidid><orcidid>https://orcid.org/0000-0003-1539-7912</orcidid><orcidid>https://orcid.org/0000-0001-6450-6930</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1535-3702 |
| ispartof | Experimental biology and medicine (Maywood, N.J.), 2023-02, Vol.248 (4), p.309-316 |
| issn | 1535-3702 1535-3699 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9902789 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central |
| subjects | Biomarkers Brief Communication COVID-19 Heme Heme Oxygenase-1 - metabolism Hemopexin - metabolism Humans Pandemics Patient Acuity |
| title | Association of heme-oxygenase 1, hemopexin, and heme levels with markers of disease severity in COVID-19 |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-23T08%3A22%3A31IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Association%20of%20heme-oxygenase%201,%20hemopexin,%20and%20heme%20levels%20with%20markers%20of%20disease%20severity%20in%20COVID-19&rft.jtitle=Experimental%20biology%20and%20medicine%20(Maywood,%20N.J.)&rft.au=de%20Lima,%20Franciele&rft.date=2023-02-01&rft.volume=248&rft.issue=4&rft.spage=309&rft.epage=316&rft.pages=309-316&rft.issn=1535-3702&rft.eissn=1535-3699&rft_id=info:doi/10.1177/15353702221139185&rft_dat=%3Cproquest_pubme%3E2773719462%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2773719462&rft_id=info:pmid/36740756&rft_sage_id=10.1177_15353702221139185&rfr_iscdi=true |